CBV regimen: Difference between revisions

	WikiDoc Resources for CBV regimen
Articles
Most recent articles on CBV regimen Most cited articles on CBV regimen Review articles on CBV regimen Articles on CBV regimen in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on CBV regimen Images of CBV regimen Photos of CBV regimen Podcasts & MP3s on CBV regimen Videos on CBV regimen
Evidence Based Medicine
Cochrane Collaboration on CBV regimen Bandolier on CBV regimen TRIP on CBV regimen
Clinical Trials
Ongoing Trials on CBV regimen at Clinical Trials.gov Trial results on CBV regimen Clinical Trials on CBV regimen at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on CBV regimen NICE Guidance on CBV regimen NHS PRODIGY Guidance FDA on CBV regimen CDC on CBV regimen
Books
Books on CBV regimen
News
CBV regimen in the news Be alerted to news on CBV regimen News trends on CBV regimen
Commentary
Blogs on CBV regimen
Definitions
Definitions of CBV regimen
Patient Resources / Community
Patient resources on CBV regimen Discussion groups on CBV regimen Patient Handouts on CBV regimen Directions to Hospitals Treating CBV regimen Risk calculators and risk factors for CBV regimen
Healthcare Provider Resources
Symptoms of CBV regimen Causes & Risk Factors for CBV regimen Diagnostic studies for CBV regimen Treatment of CBV regimen
Continuing Medical Education (CME)
CME Programs on CBV regimen
International
CBV regimen en Espanol CBV regimen en Francais
Business
CBV regimen in the Marketplace Patents on CBV regimen
Experimental / Informatics
List of terms related to CBV regimen

Newer edit →

VisualWikitext

Revision as of 18:18, 27 February 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Synonyms and keywords: BCNU/CTX/VP-16; Carmustine/Cyclophosphamide/Etoposide; CBV

Overview

CBV regimen refers to Cytoxan (cyclophosphamide), BCNU (carmustine), and VP-16 (etoposide), three drugs in a chemotherapy regimen commonly given to lymphoma patients in conjunction with stem cell therapy.^[1]

Regimen

C – Cyclophosphamide

B – Carmustine (BCNU)

V – Etoposide (VP-160)

Indications

Lymphoid malignancies^[2]

References

↑ Skeel, Roland T. Handbook of Cancer Chemotherapy, 6th Edition. Philadelphia: Lipincott, Williams, & Wilkins, 2003. Page 172-3, Table 5.4: "Common preparative regimens for high-dose therapy without total-body irradiation."
↑ William BM, Loberiza FR, Whalen V, Bierman PJ, Bociek RG, Vose JM; et al. (2013). "Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma". Clin Lymphoma Myeloma Leuk. 13 (4): 417–23. doi:10.1016/j.clml.2013.03.009. PMID 23773453.

[1] Skeel, Roland T. Handbook of Cancer Chemotherapy, 6th Edition. Philadelphia: Lipincott, Williams, & Wilkins, 2003. Page 172-3, Table 5.4: "Common preparative regimens for high-dose therapy without total-body irradiation."

[pmid23773453-2] William BM, Loberiza FR, Whalen V, Bierman PJ, Bociek RG, Vose JM; et al. (2013). "Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma". Clin Lymphoma Myeloma Leuk. 13 (4): 417–23. doi:10.1016/j.clml.2013.03.009. PMID 23773453.

[1]

[2]

@@ Line 15: / Line 15: @@
 ==Indications==
-*
+*Lymphoid malignancies<ref name="pmid23773453">{{cite journal| author=William BM, Loberiza FR, Whalen V, Bierman PJ, Bociek RG, Vose JM et al.| title=Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma. | journal=Clin Lymphoma Myeloma Leuk | year= 2013 | volume= 13 | issue= 4 | pages= 417-23 | pmid=23773453 | doi=10.1016/j.clml.2013.03.009 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23773453  }} </ref>
 ==References==
 {{Reflist|2}}
 [[Category:Chemotherapy regimens]]